Tirzepatide denied for failing step therapy by Aetna?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Tirzepatide
## Why Aetna Denied Tirzepatide Under Step Therapy
A step-therapy denial from Aetna — sometimes called a "fail-first" requirement — means the plan requires evidence that you have tried and failed one or more specific alternative medications before it will cover tirzepatide. This is among the most common barriers for tirzepatide and one of the most reliably overturned on appeal, because many patients have already trialed the required agents and simply did not document those trials in the PA submission.
Several states have also enacted step-therapy override laws that require insurers to waive step-therapy requirements when certain clinical conditions are met (e.g., contraindication, prior trial and failure, or clinical urgency). Confirm whether your state's law applies to your plan type.
## Your Appeal Rights
- ACA §2719 / ERISA §503: Federal law provides full-and-fair internal review and independent external review for most non-grandfathered group and individual plans.
- State step-therapy override laws: Depending on your state and plan type, you may have a separate statutory right to a step-therapy exception. Your prescriber's office should be aware of these.
- Internal appeal deadline: Typically 180 days from the denial; confirm on your Explanation of Benefits.
- External review window: Approximately four months from a final internal denial to file for independent external review.
- Expedited review: Available for urgent situations; request in writing simultaneously with your internal appeal.
## Documentation to Gather
1. Prior treatment history with dates and outcomes: For every drug Aetna's step-therapy protocol requires, document in the chart: the start date, the end date, the clinical response (e.g., inadequate glycemic control, intolerable adverse effects), and the reason for discontinuation. This is the single most important document in a step-therapy appeal. 2. Contraindication or clinical unsuitability: If a required step-therapy drug is contraindicated for you or clinically unsuitable based on your prescriber's judgment, that must be documented explicitly in the chart and in the prescriber's letter. 3. Diagnosis confirmation and severity: Current chart documentation of your diagnosis and objective severity indicators. 4. Prescriber medical-necessity letter: A letter that walks through each step-therapy requirement, confirms which agents were tried (with dates) or explains why they were not appropriate, and states why tirzepatide is the necessary next step. 5. Insurer policy mapping: Obtain Aetna's current step-therapy protocol for tirzepatide. List each required prior agent and document your chart's response to each, one by one.
## Criteria-Mapping Structure
A step-therapy appeal is most effective when formatted as a table: Required step-therapy agent | Dates of trial | Clinical outcome | Chart reference. Attach this table to the prescriber's letter. If any required agent was never trialed due to contraindication or unsuitability, add a column explaining the clinical basis with a chart reference.
Verify the current step-therapy requirements in Aetna's published clinical policy and review the FDA prescribing information before submitting — step protocols are updated at least annually and the current version is the one that controls your appeal.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →